headquartered in canton, massachusetts, organogenesis inc. is a global leader in regenerative medicine, offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. organogenesis’ versatile portfolio is designed to treat a variety of patients with repair and regenerative needs.
Company profile
Ticker
ORGO
Exchange
Website
CEO
Gary S. Gillheeney
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Avista Healthcare Public Acquisition Corp.
SEC CIK
Corporate docs
Subsidiaries
Organogenesis Inc. • Prime Merger Sub, LLC • Organogenesis Switzerland GmbH ...
ORGO stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Organogenesis Holdings Inc. Reports First Quarter 2024 Financial Results
9 May 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
8-K
Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case
3 Apr 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance
29 Feb 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Organogenesis Holdings Inc. Reports Third Quarter 2023 Financial Results
9 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
Transcripts
ORGO
Earnings call transcript
2024 Q1
9 May 24
ORGO
Earnings call transcript
2023 Q4
29 Feb 24
ORGO
Earnings call transcript
2023 Q3
9 Nov 23
ORGO
Earnings call transcript
2023 Q2
9 Aug 23
ORGO
Earnings call transcript
2023 Q2
9 Aug 23
ORGO
Earnings call transcript
2023 Q1
10 May 23
ORGO
Earnings call transcript
2022 Q4
1 Mar 23
ORGO
Earnings call transcript
2022 Q3
10 Nov 22
ORGO
Earnings call transcript
2022 Q2
9 Aug 22
ORGO
Earnings call transcript
2022 Q1
11 May 22
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 89.35 mm | 89.35 mm | 89.35 mm | 89.35 mm | 89.35 mm | 89.35 mm |
Cash burn (monthly) | 5.00 mm | 5.75 k | 1.45 mm | (no burn) | 3.39 mm | (no burn) |
Cash used (since last report) | 10.52 mm | 12.10 k | 3.05 mm | n/a | 7.13 mm | n/a |
Cash remaining | 78.83 mm | 89.33 mm | 86.30 mm | n/a | 82.22 mm | n/a |
Runway (months of cash) | 15.8 | 15536.3 | 59.6 | n/a | 24.3 | n/a |
Institutional ownership, Q4 2023
14.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 12 |
Opened positions | 2 |
Closed positions | 95 |
Increased positions | 3 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 4.33 bn |
Total shares | 19.19 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Ades Alan A. | 10.76 mm | $99.76 mm |
Soleus Capital Master Fund | 7.36 mm | $0.00 |
Assenagon Asset Management | 971.67 k | $3.97 bn |
SG Americas Securities | 35.77 k | $146.00 k |
Diversified Trust | 20.88 k | $85.40 mm |
Capital Square | 20.45 k | $83.64 mm |
Palumbo Wealth Management | 11.13 k | $45.53 mm |
Nisa Investment Advisors | 3.92 k | $16.01 mm |
Trivant Custom Portfolio | 3.75 k | $15.34 mm |
Barrett & Company | 1.10 k | $4.50 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | Gillheeney Gary S. | Class A Common Stock | Payment of exercise | Dispose F | No | No | 2.8 | 10,113 | 28.32 k | 2,351,949 |
1 Apr 24 | Grow Brian | Class A Common Stock | Payment of exercise | Dispose F | No | No | 2.8 | 1,977 | 5.54 k | 520,809 |
1 Apr 24 | Montecalvo Antonio S. | Class A Common Stock | Payment of exercise | Dispose F | No | No | 2.8 | 1,752 | 4.91 k | 168,268 |
1 Apr 24 | Bilbo Patrick | Class A Common Stock | Payment of exercise | Dispose F | No | No | 2.8 | 2,497 | 6.99 k | 809,082 |
News
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
10 May 24
12 Health Care Stocks Moving In Friday's Intraday Session
10 May 24
Genpact Posts Upbeat Earnings, Joins Groupon, Natera, Funko, CarGurus And Other Big Stocks Moving Higher On Friday
10 May 24
Organogenesis Hldgs Q1 2024 Adj EPS $(0.01) Beats $(0.03) Estimate, Sales $109.976M Beat $101.050M Estimate
9 May 24
Organogenesis Achieves Primary Endpoint In Phase 3 Clinical Trial Of ReNu for Knee Osteoarthritis
2 May 24
Press releases
Spotlight: Healthcare and Tech VTAK, ORGO, CDIO, LAZR, VLCN
13 May 24
Organogenesis Holdings Inc. Reports First Quarter 2024 Financial Results
9 May 24
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024
16 Apr 24
Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case
3 Apr 24